STTK
Shattuck LabsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is still a monitoring-style biotech setup: March company disclosures pointed to a near-complete Phase 1 program, Q2 2026 human data, a possible Q3 2026 Phase 2 Crohn's start, and runway guidance into 2029 that included first-quarter ATM proceeds and warrant assumptions [#8-K-2026-03-05]. If the Phase 1 package shows clean safety, durable receptor occupancy, and a credible path into Crohn's disease, the stock could move above the current median target baseline, but the weak direct peer set limits confidence in any valuation read-through.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +13.2.
What can break
No new Q1 2026 company earnings filing was located in SEC sources checked on May 4, 2026, leaving surprise, guidance, and immediate post-print reaction evidence unavailable for this T+1 run.
Momentum
55
Value
41
Sentiment
93
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.25 · Bull $9.50 · Bear $4.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $7.25
Why
Momentum55 · Δ7d -26.5
Value41 · Δ7d +0.1
Sentiment93 · Δ7d +13.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
55
34% active weight
Current posture
7d trendSoftening
Δ7d
-26.5
Δ21d
-43.5
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
93
33% active weight
Current posture
7d trendImproving
Δ7d
+13.2
Δ21d
+32.9
Why this grade
Composite grade A. Momentum 55.2 / Value 41.1 / Sentiment 93.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$433.25M
Beta
1.53
Shares Out
63.28M
P/E (TTM) · Derived
-4.6
P/S (TTM)
246.16
P/FCF (TTM) · Derived
-7.89
Rev YoY
-66.6%
EPS YoY
+57.5%
Gross Margin
-
Op Margin
-5777.8%
Net Debt
-$72.99M
Current Ratio
17.00
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology